Table 2.

Echocardiographic data of the left ventricle in a representative group of Sham and CHF rats after two weeks of Cont-shRNA or salusin-β-shRNA application.

	Sham		CHF
	Cont	Salusin-β	Cont	Salusin-β
LVEDD, mm	7.12 ± 0.23	6.76 ± 0.43	11.36 ± 0.21†	9.24 ± 0.28∗†
LVESD, mm	4.65 ± 0.13	3.49 ± 0.30	9.27 ± 0.40†	7.86 ± 0.25∗†
IVSd, mm	1.79 ± 0.05	1.70 ± 0.10	1.28 ± 0.13	1.40 ± 0.19
IVSs, mm	2.86 ± 0.13	2.93 ± 0.14	1.86 ± 0.26	1.76 ± 0.26
LVPWd, mm	1.86 ± 0.03	1.97 ± 0.12	1.63 ± 0.10	2.02 ± 0.07
LVPWs, mm	3.21 ± 0.11	3.08 ± 0.11	2.46 ± 0.30†	2.97 ± 0.08∗
FS, %	43.41 ± 1.24	48.54 ± 1.90	17.84 ± 1.02†	25.52 ± 2.01∗†
EF, %	72.60 ± 1.33	78.59 ± 1.83	34.73 ± 1.78†	47.55 ± 3.30∗†
LV mass (g)	1.19 ± 0.08	1.03 ± 0.17	1.55 ± 0.10†	1.53 ± 0.08†
LV mass/BW (mg/g)	2.81 ± 0.33	2.52 ± 0.47	3.73 ± 0.47†	3.66 ± 0.32†

LVEDD: left ventricular end-diastolic diameter; LVESD: left ventricular end-systolic diameter; IVSd: interventricular septal thickness in diastole; IVSs: interventricular septal thickness in systole; LVPWd: left ventricular posterior wall thickness in diastole; LVPWs: left ventricular posterior wall thickness in systole; FS: fractional shortening; EF: ejection fraction; LV: left ventricular; BW: body weight. Values are mean ± SE. ^∗P < 0.05 vs. Cont-shRNA. ^†P < 0.05 vs. Sham. n = 6 for each group.